Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 15/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | LIPE | Q05469 | 1/20 | 0.42 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5119266 | 0.89 | MAPK1 (0.47) | MAPK1SCN9ATHRBLMNALIPE | |
| SCHEMBL5119799 | 0.89 | MAPK1 (0.58) | MAPK1SCN9ATHRBLMNALIPE | |
| SCHEMBL5121328 | 0.89 | MAPK1 (0.52) | MAPK1SCN9ATHRBLMNALIPE | |
| SCHEMBL5120948 | 0.88 | MAPK1 (0.51) | MAPK1SCN9ATHRBLMNALIPE | |
| SCHEMBL5115379 | 0.87 | SCN9A (0.52) | MAPK1SCN9ATHRBLMNASCN10A | |
| SCHEMBL5120056 | 0.84 | PPARG (0.49) | MAPK1SCN9ATHRBLMNALIPE | |
| SCHEMBL5120469 | 0.83 | SCN9A (0.47) | MAPK1SCN9ALMNALIPESCN10A | |
| SCHEMBL5112062 | 0.81 | PPARG (0.49) | MAPK1SCN9ATHRBLMNALIPE | |
| SCHEMBL5113718 | 0.80 | MAPK1 (0.45) | MAPK1SCN9ATHRBLMNALIPE | |
| SCHEMBL5107207 | 0.79 | TSHR (0.46) | MAPK1SCN9ALMNALIPESCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | MAPK1 2249/4885SCN9A 781/4885THRB 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.